T-cell APC interface, facilitating signaling through TCR recognizing the peptide-loaded MHC molecules (26). The formation of IS was impaired *in vitro* by HIV-1 infection in a Nef-dependent manner (27), providing an explanation for the present results that Nef lowers the cognate interaction strength between T cells and APCs in antigen-specific response, thereby denying complete progression and activation of the cell cycle.

Nef affects helper T-cell activities in the primary and secondary response through different processes with different CD4 down-modulation susceptibility. However, the underlying mechanism remains obscure. In the B-cell response, antigen-activated helper T cells form a complex with B cells by interacting with several co-stimulatory molecules as well as with the TCR and peptide-loaded MHC class II molecules on B cells. As a consequence, T cells and B cells are mutually stimulated and T cells produce cytokines promoting B-cell proliferation and differentiation into antibody-forming cell (28). Therefore, it is likely that Nef-induced repression of T-cell helper activity for an antigen-specific B-cell response may also reflect an inefficient cognate interaction between T cells and B cells in the primary and secondary response.

We observed that Nef in resting murine CD4+ T cells down-regulates the expression of CD4 on the cell surface, concordant with the previous results using human and murine T-cell lines (reviewed in ref. 1). It has been previously suggested that CD4 plays an important role in the activation of T cells by increasing the avidity of TCR for the peptide/MHC class II molecule and by transducing signals through the associated tyrosine kinase p56Lck (29). CD4 down-modulation significantly affects T-cell helper activity for the primary antibody response; however, it only partially affects T-cell helper function for the secondary response. On the other hand, Nef-mediated repression of antigenspecific T-cell function for the migratory capacity in the primary immune response is not the result of CD4 downregulation. Thus, Nef affects multiple antigen-specific T-cell activities in the primary and secondary response through different processes with different CD4 down-modulation susceptibility, probably reflecting the T-cell signature and/ or B-cell signature involved in the primary or the secondary antibody response.

CD4 binds to the MHC and boosts the recognition of ligand by the TCR in early T-cell activation, afforded by the IS formation (30) and functions to deliver Lck to the T-cell APC interface (31). However, signaling and co-stimulation later result in the movement of CD4 toward the periphery of the IS (30), suggesting that once Lck has been recruited to the synapse, the function of CD4 may become dispensable, allowing CD4 to leave the synapse, compatible with the idea that initial signal strength for T-cell activation may be crucial for the primary B-cell response. Nef might affect T-cell activity to form the IS with B cells, although, it remains unknown whether primary and memory B-cell responses require the same co-receptor molecules for T-cell interaction or if they need help from the same subset of T cells. Further analysis is needed to clarify how memory and naive B-cell responses are differentially regulated.

In summary, the present results support a model in which Nef expressing HIV-1 infected CD4<sup>+</sup> T cells fail to attain multi-

ple functions required for normal immune responses. Thus, these combined effects of Nef may not facilitate extensive HIV-1 productions by increasing the numbers of productively infected cells through T-cell activations in antigen-specific immune response.

What could be the advantages for HIV-1 to inhibit proliferation and multiple T-cell functions required for immune response? Of note, Nef does not completely abrogate T-cell activation upon stimulation, as defined by expression of activated cell surface markers and a low level of cytokine production, which may allow a replicative advantage for the virus (reviewed in ref. 32). In activated CD4<sup>+</sup> T cells, viral replication is efficient and cytopathic (reviewed in ref. 32), though rapid death of infected cells may limit the production of the virus. By lowering the T-cell activity, Nef might facilitate a lowered level of viral spread and an increased infected T-cell life span by avoiding viral cytopathic effects. These cells may decay more slowly *in vivo* relative to activated cells, leading to vital consequences for the pathogenic outcome of infection in humans.

#### Supplementary data

Supplementary data are available at *International Immunology* Online.

#### **Funding**

This work was supported by a grant for Research on HIV/ AIDS from the Ministry of Health, Labor and Welfare, Japan and in part by RIKEN (K94-34200 to T.T.).

#### Acknowledgements

We thank Drs Aya Isogai for constructing the nef (mu) plasmids and Peter Burrows for critically reviewing this manuscript and Ms Yoko Nakamura and Eri Watanabe for technical assistance.

# References

- 1 Fackler, O. T. and Baur, A. S. 2002. Live and let die: Nef functions beyond HIV replication. *Immunity* 16:493.
- 2 Wang, J. K., Kiyokawa, E., Verdin, E. and Trono, D. 2000. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. *Proc. Natl Acad. Sci. USA* 97:394.
- 3 Simmons, A., Aluvihare, V. and McMichael, A. 2001. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. *Immunity* 14:763.
- 4 Manninen, A. and Saksela, K. 2002. HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells. J. Exp. Med. 195:1023.
- 5 Fortin, J. F., Barat, C., Beausejour, Y., Barbeau, B. and Tremblay, M. J. 2004. Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4<sup>+</sup> T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-κB, and AP-1 induction. J. Biol. Chem. 279:39520.
- 6 Campbell, D. J., Kim, C. H. and Butcher, E. C. 2003. Chemokines in the systemic organization of immunity. *Immunol. Rev.* 195:58.
- 7 Janardhan, A., Swigut, T., Hill, B., Myers, M. P. and Skowronski, J. 2004. HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis. *PLoS Biol*. 2:E6.
- 8 Hanna, Z., Kay, D. G., Rebai, N., Guimond, A., Jothy, S. and Jolicoeur, P. 1998. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. *Cell* 95:163.
- 9 Rahim, M. M., Chrobak, P., Hu, C., Hanna, Z. and Jolicoeur, P. 2009. Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model:

- CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphophenia. J. Virol. 83:11830.
- 10 Koenen, P. G., Hofhuis, F. M., Oosterwegel, M. A. and Tesselaar, K. 2007. T cell activation and proliferation characteristic for HIV-Nef transgenic mice is lymphopenia induced. J. Immunol. 178:5762.
- 11 Wan, Y. Y., Leon, R. P., Marks, R. et al. 2000, Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc. Natl Acad. Sci. USA 97:13784.
- 12 Murphy, K. M., Heimberger, A. B. and Loh, D. Y. 1990. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250:1720.
- 13 Kanegae, Y., Makimura, M. and Saito, I. 1994. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol. 47:157.
- 14 Takahashi, Y., Ohta, H. and Takemori, T. 2001. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 14:181.
- Choe, E. Y., Schoenberger, E. S., Groopman, J. E. and Park, I. W. 2002. HIV Nef inhibits T cell migration. J. Biol. Chem. 277:46079.
- 16 Marrack, P. and Kappler, J. 2004. Control of T cell viability. Annu. Rev. Immunol. 22:765.
- 17 Dardalhon, V., Jaleco, S., Kinet, S. et al. 2001. IL-7 differentially regulates cell cycle progression and HIV-1-based vector infection in neonatal and adult CD4+ T cells. Proc. Natl Acad. Sci. USA 98:9277
- 18 Craig, H. M., Pandori, M. W. and Guatelli, J. C. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl Acad. Sci. USA 95:11229.
- 19 Dubey, S., Khalid, M., Wesley, C., Khan, S. A., Wanchu, A. and Jameel, S. 2008. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians. J. Clin. Virol. 43:25
- 20 Venzke, S., Michel, N., Allespach, I., Fackler, O. T. and Keppler, O. T. 2006. Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surfaces of target cells and thereby enhances resistance to superinfection. J. Virol. 80:11141.

- 21 Zajac, A. J., Blattman, J. N., Murali-Krishna, K. et al. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 188:2205.
- 22 Zhang, J. et al. 2000. Regulation of fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. J. Exp. Med. 191:1017
- 23 Rhee, S. S. and Marsh, J. W. 1994. HIV-1 Nef activity in murine T cells. CD4 modulation and positive enhancement. J. Immunol.
- 24 Priceputu, E., Hanna, Z., Hu, C. et al. 2007. Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice. J. Virol. 81:4677.
- 25 Bunnell, S. C., Hong, D. I., Kardon, J. R. et al. 2002. Tcell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. 158:1263.
- 26 Dustin, M. L. 2009. The cellular context of T cell signaling. Immunity. 30:482.
- Thoulouze, M. I., Sol-Foulon, N., Blanchet, F., Dautry-Varsat, A., Schwartz, O. and Alcover, A. 2006. Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity 24:547.
- 28 Pereira, J. P., Kelly, L. M. and Cyster, J. G. 2010. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int. Immunol. 22:413.
- Veillette, A., Bookman, M. A., Horak, E. M., Samelson, L. E. and Bolen, J. B. 1989. Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck. Nature 338:257.
- 30 Krummel, M. F., Sjaastad, M. D., Wulfing, C. and Davis, M. M. 2000. Differential clustering of CD4 and CD35 during T cell recognition. Science 289:1349.
- 31 Holdorf, A. D., Lee, K. H., Burack, W. R., Allen, P. M. and Shaw, A. S. 2002. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat. Immunol. 3:259.
- 32 Stevenson, M. 2003. HIV-1 pathogenesis. Nat. Med. 9:853.

# Original Article

# Newly Established Monoclonal Antibodies for Immunological Detection of H5N1 Influenza Virus

Kazuo Ohnishi<sup>1</sup>, Yoshimasa Takahashi<sup>1</sup>, Naoko Kono<sup>2</sup>, Noriko Nakajima<sup>3</sup>, Fuminori Mizukoshi<sup>1</sup>, Shuhei Misawa<sup>4</sup>, Takuya Yamamoto<sup>1</sup>, Yu-ya Mitsuki<sup>1</sup>, Shu-ichi Fu<sup>1</sup>, Nakami Hirayama<sup>1</sup>, Masamichi Ohshima<sup>1</sup>, Manabu Ato<sup>1</sup>, Tsutomu Kageyama<sup>2</sup>, Takato Odagiri<sup>2</sup>, Masato Tashiro<sup>2</sup>, Kazuo Kobayashi<sup>1</sup>, Shigeyuki Itamura<sup>2</sup>, and Yasuko Tsunetsugu-Yokota<sup>1\*</sup>

<sup>1</sup>Department of Immunology, <sup>2</sup>Influenza Virus Research Center, and <sup>3</sup>Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640; and <sup>4</sup>Tsuruga Institute of Biotechnology, Toyobo, Co., Ltd., Fukui 914-8550, Japan

(Received October 4, 2011. Accepted October 28, 2011)

SUMMARY: The H5N1 subtype of the highly pathogenic (HP) avian influenza virus has been recognized for its ability to cause serious pandemics among humans. In the present study, new monoclonal antibodies (mAbs) against viral proteins were established for the immunological detection of H5N1 influenza virus for research and diagnostic purposes. B-cell hybridomas were generated from mice that had been hyperimmunized with purified A/Vietnam/1194/2004 (NIBRG-14) virion that had been inactivated by UV-irradiation or formaldehyde. After screening over 4,000 hybridomas, eight H5N1-specific clones were selected. Six were specific for hemagglutinin (HA) and had in vitro neutralization activity. Of these, four were able to broadly detect all tested clades of the H5N1 strains. Five HA-specific mAbs detected denatured HA epitope(s) in Western blot analysis, and two detected HP influenza virus by immunofluorescence and immunohistochemistry. A highly sensitive antigen-capture sandwich ELISA system was established by combining mAbs with different specificities. In conclusion, these mAbs may be useful for rapid and specific diagnosis of H5N1 influenza. Therapeutically, they may have a role in antibody-based treatment of the disease.

#### INTRODUCTION

The highly pathogenic (HP) H5N1 avian influenza virus caused the first outbreak in humans in Hong Kong in 1997. This outbreak resulted in the infection of 18 people and resulted in six deaths (1,2). Thereafter, it was determined that H5N1 avian influenza virus was continuously circulated among geese in Southeastern China. Eventually, it spread to other Southeast Asian countries, where it severely damaged poultry farms (3,4). Subsequent H5N1 outbreaks in humans occurred in China and Vietnam in 2003 and in Indonesia in 2005. The most recent endemic has occurred in Egypt. According to a World Health Organization report, the H5N1 avian influenza virus had infected 565 people and resulted in 331 deaths by August 19, 2011 (5). Therefore, although sporadic, this fatal human infection is persistent and has the potential to cause serious future pandemics.

In humans, infection with HP H5N1 avian influenza virus causes high fever, coughing, shortness of breath, and radiological findings of pneumonia (6–8). In severe cases, rapidly progressive bilateral pneumonia develops, causing respiratory failure and may be responsible for the high mortality associated with this virus. de Jong et

al. analyzed human cases of H5N1 infection and found that a high viral load and the resulting intense inflammatory response caused severe symptoms; furthermore, viral RNA was frequently detected in the rectum, blood, and nasopharynx (9). Thus, it is essential to detect HP influenza virus infection early and rapidly in order to provide early interventions that protect patients from devastating respiratory failure that arises from a high viral load. Additionally, early viral detection would facilitate rapid identification of infected patients and prevent unregulated contact with other people.

The present diagnostic standard for HP H5N1 influenza is the presence of the neutralization antibody. However, it takes more than 1 week for H5N1-specific antibodies to develop, and a well-equipped biosafety level 3 (BSL3) laboratory is required for the virus neutralization assay. A simpler method is the hemagglutination-inhibition assay using horse erythrocyte. This method has been widely performed on paired acute and convalescent sera from patients with HP H5N1 influenza virus infections. Although this method has acceptable sensitivity, its specificity has been questioned (7).

Isolating the virus from patient samples is the gold standard for diagnosing an infection; however, this is not always possible. For example, the method of sample preparation and preservation strongly influence the ability to isolate the virus. Moreover, a BSL3 laboratory is essential. At present, the most sensitive and rapid method for initial diagnosis of H5N1 virus infections is by conventional or real-time reverse-transcriptase polymerase chain reaction (RT-PCR). However, this proce-

<sup>\*</sup>Corresponding author: Mailing address: Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan. Tel: +81-3-5285-1111, Fax: +81-5285-1150, E-mail: yyokota@nih.go.jp

dure requires expertise in molecular virology and expensive equipment and reagents. Moreover, because of its high sequence specificity, this approach could fail to identify mutant influenza viruses that continually evolve due to a high mutation rate (8).

For screening suspected H5N1 influenza virus in the field, the ideal approach would be to employ an immunology-based technique that detects viral antigens. Such a method is simple and rapid. However, its sensitivity and specificity depend highly on the antibodies used. Thus, an immunological assay that uses appropriate specific antibodies against H5N1 in combination with specific antibodies against other subtypes of influenza virus or viruses that cause febrile diseases would be useful for screening in areas with endemic influenza-like illness. While there are several rapid influenza virus diagnostic systems available for seasonal influenza (10), few exist for H5N1 influenza. Therefore, we have developed a simple and rapid diagnostic system with high sensitivity and specificity for H5N1 influenza virus.

Influenza virus belongs to the family Orthomyxoviridae; its genome consists of a negative-sense, singlestranded RNA with eight segments, each encoding structural and non-structural proteins (11). Influenza A viruses are classified into several subtypes based on the hemagglutinin (HA) and neuraminidase (NA) serotypes. In total, there are 16 HA and 9 NA serotypes. The H5N1 viruses are divided into clades 1 and 2 based on their HA genotypes. Clade 2 has been further subdivided into five sub-clades (12). Clade 1 viruses were predominant in Vietnam, Thailand, and Cambodia in the early phase of the 2004-2005 outbreak, whereas clade 2.1 viruses were endemic in Indonesia at that time (8). These two viruses are the major prototypes for the preparation of prepandemic H5N1 vaccines. We used inactivated purified clade 1 virion [A/Vietnam/1194/ 2004 (NIBRG-14)] as an immunizing antigen to establish mouse monoclonal antibodies (mAbs) specific for H5N1 influenza virus. Characterization of these mAbs revealed that they could detect H5N1 viruses when used in an immunofluorescence staining assay (IFA), Western blotting analysis, immunohistochemistry, and antigen-capture sandwich ELISA. In addition, the mAbs had significant in vitro neutralization activity against H5N1 viruses, and some broadly detected both clade 1 and 2 viruses.

### MATERIALS AND METHODS

Viruses and cell culture: The NIBRG-14 (H5N1) virus, which possesses modified HA and NA genes derived from the A/Vietnam/1194/2004 strain on the backbone of six internal genes of A/Puerto Rico/8/34 (PR8), was provided by the National Institute for Biological Standards and Controls (NIBSC; Potters Bar, UK). A/Indonesia/05/2005 (Indo5/PR-8-RG2), A/Turkey/1/2005 (NIBRG-23), A/Anhui/01/2005 (Anhui01/PR8-RG5) were also obtained from NIBSC. All non-H5N1 strains were obtained from a stockpile of seed vaccines of the Influenza Virus Research Center of the National Institute of Infectious Diseases. The live virus was manipulated in a BSL2 laboratory. To produce and purify the virion, the NIBRG-14 and PR8 viruses were propagated in the allantoic cavity of 10-day-old

embryonated hens' eggs and purified through a 10-50% discontinuous sucrose gradient by ultracentrifugation (13). The viruses were then resuspended in phosphate-buffered saline (PBS) and inactivated by ultraviolet (UV) irradiation or by treatment with 0.05% formalin at 4°C for 2 weeks. These preparations were served as the inactivated H5N1 virus fraction. These conditions have been previously shown to completely inactivate H5N1 viruses.

Production of mAbs: Nine-week-old female BALB/c mice (Japan SLC, Shizuoka, Japan) were immunized subcutaneously with 20 µg of UV- or formaldehydeinactivated NIBRG-14 (H5N1) virus using Freund's Complete Adjuvant (Sigma, St. Louis, Mo., USA). Two weeks later, the mice were boosted with a subcutaneous injection of  $5 \mu g$  of the inactivated virus emulsified with Freund's Incomplete Adjuvant (Sigma). Three days after the boost, sera from the mice were tested by ELISA to determine the antibody titer against the NIBRG-14 virus. The three mice with the highest antibody titers were given an additional boost 14 days after the first boost by intravenous injection of 5  $\mu$ g of the inactivated virus. Three days later, the spleens of these three mice were excised, and the spleen cells were fused with Sp2/O-Ag14 myeloma cells using the polyethylene glycol method of Kozbor and Roder (14). The fused cells were cultured on twenty 96-well plates and selected with hypoxiantine-aminopterin-thymidine (HAT) medium. The first screening was conducted by ELISA using formalin-inactivated purified NIBRG-14 (H5N1) and PR-8 (H1N1) virions, which were lysed with 1% Triton X100. The lysates (1 mg/ml) were diluted 2,000-fold with ELISA-coating buffer (50 mM sodium bicarbonate, pH 9.6), and the ELISA plates (Dynatech, Chantily, Va., USA) were coated at 4°C overnight. After blocking with 1% ovalbumin in PBS-Tween (10 mM phosphate buffer, 140 mM NaCl, 0.05% Tween 20, pH 7.5) for 1 h, the culture supernatants of the HAT-selected hybridomas were added and incubated for 1 h. After washing with PBS-Tween, the bound antibodies were detected using alkaline phosphatase-conjugated antimouse IgG (1:2,000; Zymed, South San Francisco, Calif., USA) and p-nitrophenyl phosphate, which served as a substrate. In this first screening, hybridomas that reacted to the H5N1 virus (NIBRG-14) but not to the H1N1 virus (PR-8) were selected.

Baculoviral expression of recombinant HA and NA: Recombinant HA (rHA) and NA (rNA) proteins were produced as previously described (13). Briefly, the HA-and NA-coding genes of NIBRG-14 were amplified by PCR to attach a 6x-His tag to the C terminus of HA and to the N terminus of NA. The amplified DNAs were then cloned into pBacPAK8 (Clontech, Mountain View, Calif., USA) and transfected into Sf-21 (Spodoptera frugiperda) insect cells. Recombinant baculoviruses containing the rHA and rNA genes were isolated were used to infect Sf-21 cells. The recombinant proteins tagged with 6x-His were purified with TALON columns (Clontech) according to the manufacturer's protocol.

Neutralization assay: For the neutralization assay, 100 TCID<sub>50</sub> of H5N1 virus, a standard tissue culture infectious dose for such assays, was incubated for 30 min at 37°C in the presence or absence of the purified mAbs, which had been serially diluted twofold. The viruses

were then added to MDCK cell cultures that had been grown to confluence in a 96-well microtiter plate. The virus strains used were A/Vietnam/1194/2004 (NIBRG-14) (H5N1) (clade 1), A/Indonesia/05/2005 (Ind05/PR8-RG2) (H5N1) (clade 2.1), A/Turkey/1/2005 (NIBRG-23) (H5N1) (clade 2.2), and A/Anhui/01/2005 (Anhui01/PR8-RG5) (H5N1) (clade 2.3). After 3-5 days, the cells were fixed with 10% formaldehyde and stained with crystal violet to visualize the cytopathic effects induced by the virus (15). Neutralization antibody titers were expressed as the minimum concentration of purified immunoglobulin that inhibited a cytopathic effect.

Western blot analysis: UV-inactivated purified H5N1 virus (0.5 µg/lane) was loaded on SDS-PAGE gels under reducing conditions. The proteins were then transferred to a PVDF membrane (Genetics, Tokyo, Japan). After blocking with BlockAce reagent (Snow Brand Milk Products Co., Tokyo, Japan), the membranes were detected with the mAbs or diluted sera (1:1,000) that had been obtained from mice immunized with UV-irradiated H5N1 virus. After washing, the membrane was reacted with the peroxidase-conjugated F(ab')<sub>2</sub> fragment of anti-mouse IgG (H+L) (1:20,000; Jackson ImmunoResearch, West Grove, Pa., USA), and the bands were visualized on X-ray film (Kodak, Rochester, N.Y., USA) with chemiluminescent reagents (Amersham Biosciences, Piscataway, N.J., USA).

Purification and biotinylation of mAbs: Hybridomas were grown in Hybridoma-SFM medium (Invitrogen, Carlsbad, Calif., USA) supplemented with recombinant IL-6, penicillin (100 U/mL), and streptomycin (100  $\mu$ g/mL) (16). The culture supernatants were harvested, and 1/100 volume of 1 M Tris-HCl (pH 7.4) and 1/500 volume of 10% NaN<sub>3</sub> were applied directly on a Protein G-Sepharose 6B column (Amersham Biosciences). The column was washed with PBS and eluted with glycine/HCl (pH 2.8). After measuring the  $OD_{280}$  of the fractions, the protein-containing fractions were pooled, and an equal volume of saturated (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> was added. The precipitated proteins were dissolved in PBS, dialyzed against PBS, and stored at  $-20^{\circ}$ C. The purified antibodies were biotinylated with sulfo-NHS-LCbiotin (Pierce, Rockford, Ill., USA) according to the manufacturer's protocol.

Antigen-capture ELISA: The purified antigen-capturing mAb was immobilized on a microplate (Immulon 2; Dynatech) by incubating  $4 \mu g/mL$  of the mAb in 50 mM sodium bicarbonate buffer (pH 8.6) at 4°C overnight. The microplate was blocked with 1% BSA, washed with PBS-Tween, and reacted with serial dilutions of UV-inactivated purified H5N1 virus for 1 h at room temperature. After washing with PBS-Tween, biotinylated probing mAb (0.1  $\mu$ g/mL) was added to the wells for 1 h at room temperature. After washing, horseradish peroxidase (HRP)-labeled streptavidin (Zymed) was added to the wells for 1 h at room temperature. After washing, 0.4 mg/mL o-phenylenediamine (OPD Sigma P-8412) in OPD Buffer (0.05 M citratephosphate buffer pH 5.0, 0.04% H<sub>2</sub>O<sub>2</sub>) or TMB(+) substrate (DAKO, Kyoto, Japan) was added. The reaction was stopped by adding 2N H<sub>2</sub>SO<sub>4</sub>, and the OD<sub>490</sub> or OD<sub>450</sub> was measured using a multi-well plate reader (Flow Laboratories Inc., Inglewood, Calif., USA).

Immunohistochemistry: Lung tissues were harvested from mice infected with A/Vietnam/1194/2004 (NIBRG-14) or A/HongKong/483/97 (HK483). In addition, autopsied lung tissues of patients infected with influenza virus (H1N1 or 2009 H1N1pdm) were used. Formaldehyde- or formalin-fixed paraffin-embedded lung tissue sections were deparaffinized with xylene and graded ethanol and then autoclaved in 0.1 M citratebuffer (pH 6.0) at 121°C for 10 min to retrieve the antigens. Endogenous peroxidase was inactivated with 0.3% hydrogen peroxide for 30 min at room temperature. After blocking with M.O.M. blocking reagent (Vector laboratories, Burlingame, Calif., USA) or 5% goat serum, the sections were incubated with each of the mouse mAbs or rabbit polyclonal antibody against type A influenza nucleoprotein at 4°C overnight. After washing off the excess antibodies, the sections were incubated with HRP-labeled anti-mouse IgG followed by tyramide signal amplification system (Biotin-free catalyzed amplification system, CSAII; DAKO) or biotinylated anti-rabbit IgG followed by streptavidin/HRP (LSAB kit; DAKO). The labeled peroxidase activity was detected using diaminobenzidine (DAB; Dojin, Kumamoto, Japan) in 0.015% hydrogen peroxide/ 0.05 M Tris-HCl (pH 7.6). The sections were counterstained with hematoxylin.

#### RESULTS

Generation of H5N1-specific mAbs: To establish hybridomas that secrete mAbs specific for the H5N1 virus, BALB/c mice were immunized with the whole virion fraction of purified A/Vietnam/1194/2004 (NIBRG-14) virus. The virus had been inactivated by conventional formaldehyde-fixation or by UV-irradiation to avoid possible changes in antigenicity caused by aldehyde fixation. A standard immunization protocol was used, where mice were boosted twice at 2-week intervals with antigen emulsified first in Freund's Complete Adjuvant and then in Freund's Incomplete Adjuvant. Three days after the final boost, a cell suspension was prepared from the spleens of three immunized mice and fused with SP-2/O myeloma using a polyethylene-glycol method. The fused cells were then selected with HAT (14). Hybridoma screening yielded eight hybridoma clones that reacted to NIBRG-14 lysate but not PR-8 lysate in ELISA (Table 1). Of these clones, seven were from mice immunized with UV-inactivated virion, and one was from mice immunized with formaldehyde-inactivated virion. Six clones (Niid\_H5A, Niid\_ H5B, Niid\_H5C, Niid\_H5D, Niid\_H5E, and Niid\_ H5F) reacted to rHA protein from a H5N1 virus (recHA \_H5N1), while one clone (Niid\_N1A) reacted to rNA protein from a H5N1 virus (recNA\_H5N1). The remaining clone (Niid 150KA) did not react to either recHA H5N1 or recNA\_H5N1 by ELISA but did react to a 150-kDa molecule on Western blot analysis (described below). Interestingly, seven of the eight clones were from the mice immunized with UV-inactivated virus. The eight hybridomas were successfully cloned by a repeated limiting-dilution method and adapted to a serum-free hybridoma culture medium. The purified antibodies from each clone were biotinylated and used for further experiments.

Table 1. Summary of the eight H5N1-specific mAbs generated in this study

Clone name	Old name	Ig-subclass	ELISA			337			N		
			H5N1_ NIBRG-14	H1N1_ PR-8	recHA_ H5N1	recNA_ H5N1	Western blot	IFA	A Histology	Neutralization (μg/mL)	Hemagglutination inhibition
Niid_H5A1)	YH-1A1	IgG2a	+++	-	+		57 kDa	++		1.5 (Clade-dep)	
Niid_H5B <sup>1)</sup>	YH-2F11	IgG2a	+++	_	+++		57 kDa			25	+
Niid_H5C1)	OM-A	IgG2a	+++	-	++	-	57 kDa		+(mo/hu)	12	
Niid_H5D <sup>1)</sup>	OM-B	IgG2a	+++	_	++		57 kDa		+ (mo)	12	
Niid_H5E <sup>1)</sup>	OM-C	IgG2a	+++	-	++		57 kDa			12 (Clade-dep)	
Niid_H5F	AY-2C2	IgG1	+++	-	++ ,	_	ND	++		6	_
Niid_N1A1)	YH-2D3	lgG2a	+++	_		+	ND	++			
Niid_150KA <sup>1)</sup>	OM-D	IgG1	+++			_	150 kDa	++			_

<sup>1):</sup> Clones derived from mice immunized with UV-inactivated virus. The remaining clone is derived from a mouse immunized with formaldehyde-inactivated virus.




Fig. 1. Detection of influenza virus proteins in Western-blot analysis. Purified influenza virus proteins (0.5 μg/lane) were subjected to SDS-PAGE under reducing conditions. After blotting on a PVDF membrane, the proteins were detected by incubation with the eight monoclonal antibodies (mAbs), followed by incubation with the peroxidase-labeled F(ab')<sub>2</sub> fragment of donkey anti-mouse IgG. The mAbs were then visualized by chemiluminescent reaction. A, authentic anti-H5\_hemagglutinin mAb; B, authentic anti-H5\_neuraminidase mAb; C, authentic anti-H1\_hemagglutinin mAb; D, Niid\_H5A; E, Niid\_H5E; F, Niid\_H5F; G, Niid\_150KA. The molecular weight markers are shown on the left.

Western blot analyses with the mAbs: Five mAbs (Niid\_H5A, Niid\_H5B, Niid\_H5C, Niid\_H5D, Niid\_H5E) detected the 57-kDa H5\_H1 protein by Western blot analysis, which suggests that the antibodies detected the linear epitope(s) of a HA1 fragment of H5\_HA (Table 1 and Fig. 1). These antibodies also detected the 60-kDa recombinant H5-HA containing the His-tag. One of these clones, Niid\_H5E, detected a 40-kDa subfragment of recombinant HA1, which suggests that the antigenic footprint detected by the mAb differs from

that of the other four clones (Fig. 1). Niid-H5F, which reacted strongly to NIBRG-14 and rHA (H5) in ELISA, did not react to any proteins by Western blot analysis, presumably because the mAb detects a conformational epitope of H5-HA. The remaining clone, Niid\_150KA, detected an unknown high molecular weight protein of approximately 150 kDa.

IFA with mAbs: Upon IFA, the HA-specific mAbs Niid-H5A and Niid\_H5F, the NA-specific mAb Niid-N1A, and the Niid\_150KA mAb that detects an




Fig. 2. Fluorescent immunostaining of H5N1 virus-infected MDCK cells with monoclonal antibodies (mAbs). Paraformaldehyde-fixed, H5N1 virus-infected MDCK cells were permeabilized by TBS-Tween and incubated with biotinylated mAbs. The mAbs were detected with Qdot655-conjugated streptavidin (red). Shown are representative staining patterns with Niid\_H5A, Niid\_H5F, Niid\_N1A, and Niid\_150KA. The negative control staining without mAb is shown on top. The nuclei were counterstained with DAPI (blue).

unknown 150-kDa protein bound to NIBRG-14-infected MDCK cells (Fig. 2). With the exception of Niid\_H5F, these mAbs detected both the perinuclear region and the cell surface of NIBRG-14-infected MDCK cells. Niid\_H5F did not detect the perinuclear region (presumably the Golgi body), which suggests that the antigenic footprint detected by this mAb differs from those of the other mAbs.

Immunohistochemistry: The Niid\_H5C and Niid H5D mAbs detected influenza virus antigens in the epithelial cells of the bronchioles and alveoli of 4% formaldehyde-fixed, paraffin-embedded lung tissue sections from mice infected with A/Vietnam/1194/2004 (NIBRG-14) (Fig. 3a). However, none of the mAbs detected influenza virus antigen in lung tissue sections from mice infected with A/HongKong/483/97 (HK483) (Fig. 3). In contrast, a polyclonal antibody against type A influenza nucleoprotein detected type A influenza virus nucleoprotein in the tissue sections from both the NIBRG-14- and HK483-infected mice (Fig. 3b, d). Thus, Niid\_H5C and Niid\_H5D specifically detected the HA antigen of A/Vietnam/1194/2004 (NIBRG-14). The specificity of these mAbs was then examined by using autopsied lung tissue sections from patients infected with seasonal influenza virus (H1N1) or 2009 pandemic influenza virus (2009H1N1pdm). Niid\_H5C did not exhibit any crossreactivity, but the Niid\_H5D mAb did show non-specific staining with the human lung section. Two other mAbs, Niid\_H5B and Niid\_N1A, were also subjected to such immunohistochemical analysis but did not show any reaction.

Neutralization assay with mAbs: The ability of the mAbs to neutralize several H5N1 influenza strains was then tested (Table 2). The four purified H5N1 virus strains, NIBRG-14, Indo-RG2, NIBRG-23, and Anhui-RG5, were diluted to  $2-3 \times 10^2 \text{ TCID}_{50}/0.05 \text{ mL}$  (Table 2, lower panel) and incubated with titrated amounts of anti-H5\_HA mAbs. The remaining infectivity was then noted (Table 2, upper panel). Niid\_H5A most potently neutralized the NIBRG-14 strain; it completely neutralized influenza virus infectivity at a concentration of 78 ng/mL. However, Niid\_H5A was less potent in neutralizing the Indo-RG2 and Anhui-RG5 strains, which indicates that the neutralizing ability of this mAb was clade-dependent. In contrast, Niid H5F and Niid H5D exhibited relatively broad neutralizing abilities, since they neutralized all of the strains that were tested. Niid\_ H5C and Niid\_H5E also showed characteristic clade-




Fig. 3. Immunohistochemical analyses of lung sections from mice infected with A/Vietnam/1194/2004 (NIBRG-14) or A/HongKong/483/97 (HK483) virus. (a, b) Influenza virus antigens were detected in the epithelial cells of the bronchioles and alveoli of the mouse infected with A/Vietnam/1194/2004 (NIBRG-14) by the Niid\_H5C clone (a) and polyclonal antibody against type A influenza nucleoprotein (b). (c, d) Virus antigens were not detected in the lung tissue section of the mouse infected with A/HongKong/483/97 (HK483) when Niid\_H5C was used (c). However, virus antigens were detected in this section when a polyclonal antibody against type A influenza nucleoprotein was employed (d).

Table 2. Neutralizing ability of the eight mAbs generated in this study

	Neutralizing antibody titer (ng/mL)							
Clone	NIBRG-14 (clade 1)	Indo-RG2 (clade 2.1)	NIBRG-23 (clade 2.2)	Anhui-RG5 (clade 2.3)				
Niid_H5A	78	>10,000	625	>10,000				
Niid_H5C	625	625	313	>10,000				
Niid_H5D	625	625	313	5,000				
Niid_H5E	625	>10,000	>10,000	>10,000				
Niid_H5F	313	313	156	2,500				

Test no.	Virus infection index (Log <sub>10</sub> TCID <sub>50</sub> /0.05 mL)							
rest no.	NIBRG-14	Indo-RG2	NIBRG-23	Anhui-RG5				
1	2.5	3.1	2.4	2.1				
2	2.0	NT	2.0	2.4				

The in vitro neutralization assay examined the ability of the mAbs to neutralize H5N1 virus infection of cultured MDCK cells. Briefly, purified H5N1 virus was diluted to  $2\text{-}3\times10^2$  TCID $_{50}/0.05$  mL (the quantities are shown in the lower table) and incubated with serially-titrated purified mAbs for 1 h at 37°C. The samples were then placed into 96-well plates in which MDCK cells had been grown to 90% confluence. After 48 h, the cytotoxicity of the mAbtreated viruses was visualized by staining the cells with crystal violet. NT, not tested.

dependency, suggesting that the epitopes of these mAbs differ. Interestingly, the mAbs were least able to neutralize Anhui-RG5. This may reflect the genetic distance between Anhui-RG5 (clade 2.3) and NIBRG-14 (clade 1).

Antigen-capture ELISA: To quantitatively detect H5N1 virus, we constructed a sandwich ELISA-based virus antigen-capture detection system. Preliminary experiments tested all combinations of two mAbs from the

eight mAbs; Niid\_H5F had the highest detection sensitivity for purified H5N1 virion and reacted broadly to the H5\_HA of viruses belonging to clades 1, 2.1, 2.2, and 2.3. Therefore, Niid\_H5F was selected as the antigen-capturing mAb. The antigen-capture ELISA was constructed by immobilizing Niid\_H5F (and/or Niid\_H5C) on the ELISA plate and using biotinylated Niid\_H5D as the detection mAb, since this combination gave the best results (data not shown). Since the eight mAbs




Fig. 4. ELISA reactivity of the Niid\_H5A and Niid\_H5F monoclonal antibodies (mAbs) to various influenza virus strains. Different influenza virus strains were immobilized on 96-well plates and incubated with biotinylated Niid\_H5A or Niid\_H5F mAbs followed by peroxidase-labeled streptavidin. The binding of the mAbs was then quantitated by a colorimetric assay using TMB as a substrate.

were originally raised against the H5N1 virus strain A/Vietnam/1194/2004 (NIBRG-14), the validity of this system with other strains of H5N1 virus was also examined. As shown in Fig. 4, this system could detect the A/Indonesia/05/2005 (Indo5/PR-8-RG2), A/Turkey/1/2005 (NIBRG-23), and A/Anhui/01/2005 (Anhui01/PR8-RG5) strains but none of the non-H5N1 strains. The sandwich ELISA could detect H5N1 virus protein at concentrations as low as 50 ng/mL HA, namely, >3 SD of negative samples (Fig. 5).

#### DISCUSSION

In the present study, mAbs against H5N1 influenza virus were established. These mAbs could detect the virus when used in Western blot analyses, IFA, immunohistochemical analyses, neutralization assays, and antigen-capture ELISA. The characteristics of the mAbs are summarized in Table 1.

Of the eight mAb clones that reacted to H5N1 virus in ELISAs, six reacted to rHA. Only one clone reacted to NA protein. Another clone detected an unknown 150-kDa molecule upon Western blot analysis. A hybridoma that secreted a mAb that could detecte the nuclear protein or other protein components of H5N1 virus was

not detected, presumably because the first screening step identified H5 specificity. These results indicate that the HA protein is a dominant target in the antibody response of HA-subtype specificity, as suggested by other studies (17,18). There is accumulating evidence that the influenza strain-specific epitopes are often localized on the HA1 region, whereas the epitopes that are conserved among various strains are localized on the HA2 region (19-22). It has been reported that the immune response elicited by H1N1pdm yields a high frequency of HA2-specific mAbs (23,24). In the present study, none of the established clones detected the HA2 fragment of H5HA, presumably because this study focused on H5-specific clones.

The mAbs isolated in the present study were assessed for their ability to detect H5N1 virus-infected MDCK cells in IFA. Indeed, the anti-HA and anti-NA mAbs detected the cytoplasmic Golgi-rich region and the cell surface membrane. This reflects the common assembly process of influenza virus (25).

In general, a single diagnostic test is not reliable because of the potential for false positives and negatives. Considering the restricted availability of RNA detection systems (26,27), serological screening systems other than those that detect antibodies are currently being ex-




Fig. 5. Antigen-capture ELISA reactivity of monoclonal antibodies (mAbs) to H5N1 and H1N1 virus strains. The anti-H5 mAb Niid\_H5F was immobilized on 96-well plates and reacted with serially-titrated purified H5N1 virus fractions for 1 h at room temperature. The bound virus proteins were detected by incubation with biotinylated Niid\_H5D (anti-H5) antibody followed by peroxidase-labeled streptavidin. The binding was quantitated by a colorimetric assay that used TMB as a substrate. Abscissa, concentration of purified H5N1 virus proteins. Ordinate, absorbance unit (OD490).

amined. ELISA-based antigen-capture assays offer high specificity and reproducibility and have been used to diagnose and monitor many diseases. The present study describes the development of an antigen-capture ELISA system that detects purified H5N1 virus virion at levels as low as 50 ng/mL. The sensitivity of this system, which comprises three anti-HA mAbs, appears sufficiently high to detect virus protein in patient sera, particularly since a recently reported antigen-capture ELISA system detects 50 ng/mL of purified recombinant HA1 protein (28). At present, the sensitivity of the system is being improved, and its usefulness in diagnosing and monitoring H5N1 virus infections is being validated.

The five selected anti-HA mAbs exhibited significant neutralization activity against several viral strains in a clade-dependent manner (Table 2). Of these, Niid\_H5F showed the broadest spectrum of neutralization activity, but it neutralized NIBRG-23 (clade 2.2) more efficiently than the original immunogen NIBRG-14 (clade 1). It would be of interest to determine the features that determine this clade-dependency of mAb recognition. It is also possible that these mAbs have therapeutic potential, if humanized by means of complementarity determining region grafting or mouse-human chimerism.

In conclusion, eight new H5N1-specific mAbs were generated from A/Vietnam/1194/2004 (NIBRG-14)-hyperimmunized mice, six of which were HA-specific. These mAbs were useful in Western blot analyses, IFA, and immunohistology and had in vitro neutralization activity against H5N1 viruses. These mAbs also perform well in a highly sensitive antigen-capture sandwich

ELISA system. As such, these mAbs may be useful for the rapid and specific diagnosis of H5N1 subtype influenza virus and may have therapeutic potential.

Acknowledgments We are grateful to Ms. Sayuri Yamaguchi, Yuko Sato, and Yukari Hara for their assistance in establishing the hybridomas. We also thank Dr. Le Mai Thi Quynh at the National Institute of Hygiene and Epidemiology, Vietnam for supplying the A/Vietnam/1194/2004 virus and Dr. John Wood at NIBSC for providing the NIBRG-14 virus.

This work was supported by grants from the Ministry of Health, Labour and Welfare of Japan and from Health Science Foundation of Japan.

Conflict of interest None to declare.

#### REFERENCES

- Chan, M.C., Cheung, C.Y., Chui, W.H., et al. (2005): Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res., 6, 135.
- World Health Organization Global Influenza Program Surveillance Network (2005): Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis., 11, 1515-1521.
- Webster, R.G. and Govorkova, E.A. (2006): H5N1 influenza—continuing evolution and spread. N. Engl. J. Med., 355, 2174-2177.
- Webster, R.G., Guan, Y., Peiris, M., et al. (2002): Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern china. J. Virol., 76, 118-126.
- World Health Organization: Online at <a href="http://www.who.int/csr/disease/avian\_influenza/country/cases\_table\_2011\_2008\_2019/en/index.html">http://www.who.int/csr/disease/avian\_influenza/country/cases\_table\_2011\_2008\_2019/en/index.html</a>.
- Uyeki, T.M. (2009): Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin. Infect. Dis., 49, 279-290.

- 7. Gambotto, A., Barratt-Boyes, S.M., de Jong, M.D., et al. (2008): Human infection with highly pathogenic H5N1 influenza virus. Lancet, 371, 1464-1475.
- Abdel-Ghafar, A.N., Chotpitayasunondh, T., Gao, Z., et al. (2008): Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med., 358, 261-273.
- 9 de Jong, M.D., Simmons, C.P., Thanh, T.T., et al. (2006): Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med., 12, 1203-1207.
- Centers for Disease Control and Prevention: Seasonal Influenza (Flu). Influenza Diagnostic Testing Algorithm. Online at http://www.cdc.gov/flu/professionals/diagnosis/testing\_algorithm.htm>.
- 11. Wright, P.F., Neumann, G. and Kawaoka, Y. (2007): Orthomyx-oviridae. Lippincott Williams & Wilkins, Philadelphia.
- 12. World Health Organization: Influenza Continuing Progress towards a Unified Nomenclature System for the Highly Pathogenic H5N1 Avian Influenza Viruses. Online at http://www.who.int/influenza/resources/documents/h5n1 nomenclature/en/.
- 13. Takahashi, Y., Hasegawa, H., Hara, Y., et al. (2009): Protective immunity afforded by inactivated H5N1 (nibrg-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J. Infect. Dis., 199, 1629-1637.
- Kozbor, D. and Roder, J.C. (1984): In vitro stimulated lymphocytes as a source of human hybridomas. Eur. J. Immunol., 14, 23-27.
- Storch, G.A. (2001): Diagnostic virology. p. 493-531. Lippincott Williams & Wilkins, Philadelphia.
- Ohnishi, K., Sakaguchi, M., Kaji, T., et al. (2005): Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn. J. Infect. Dis., 58, 88-94.
- 17. Graves, P.N., Schulman, J.L., Young, J.F., et al. (1983): Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology, 126, 106-116.
- Russ, G., Polakova, K., Kostolansky, F., et al. (1987): Monoclonal antibodies to glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. Acta Virol., 31, 374-386.

- 19. Kashyap, A.K., Steel, J., Oner, A.F., et al. (2008): Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. USA, 105, 5986-5991.
- Throsby, M., van den Brink, E., Jongeneelen, M., et al. (2008): Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IGM+memory B cells. PLoS One, 3, e3942.
- 21. Sui, J., Hwang, W.C., Perez, S., et al. (2009): Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol., 16, 265-273.
- Ekiert, D.C., Bhabha, G., Elsliger, M.A., et al. (2009): Antibody recognition of a highly conserved influenza virus epitope. Science, 324, 246-251.
- Corti, D., Suguitan, A.L., Jr., Pinna, D., et al. (2010): Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest., 120, 1663-1673.
- Wrammert, J., Koutsonanos, D., Li, G.M., et al. (2011): Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med., 208, 181-193.
- Palese, P. and Shaw, M.L. (2007): Orthomyxoviridae: the viruses and their replication. p. 1647. Lippincot Williams & Wilkins, Philadelphia.
- Imai, M., Ninomiya, A., Minekawa, H., et al. (2007): Rapid diagnosis of H5N1 avian influenza virus infection by newly developed influenza H5 hemagglutinin gene-specific loop-mediated isothermal amplification method. J. Virol. Methods, 141, 173-180.
- 27. Wei, H.L., Bai, G.R., Mweene, A.S., et al. (2006): Rapid detection of avian influenza virus a and subtype H5N1 by single step multiplex reverse transcription-polymerase chain reaction. Virus Genes, 32, 261-267.
- 28. He, Q., Velumani, S., Du, Q., et al. (2007): Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clin. Vaccine Immunol., 14, 617-623.





# **ARTICLE**

Received 14 Nov 2011 | Accepted 11 Jan 2012 | Published 14 Feb 2012

DOI: 10.1038/ncomms1677

# Interferon-γ-producing immature myeloid cells confer protection against severe invasive group A Streptococcus infections

Takayuki Matsumura<sup>1</sup>, Manabu Ato<sup>1</sup>, Tadayoshi Ikebe<sup>2</sup>, Makoto Ohnishi<sup>2</sup>, Haruo Watanabe<sup>2</sup> & Kazuo Kobayashi<sup>1</sup>

Cytokine-activated neutrophils are known to be essential for protection against group A *Streptococcus* infections. However, during severe invasive group A *Streptococcus* infections that are accompanied by neutropenia, it remains unclear which factors are protective against such infections, and which cell population is the source of them. Here we show that mice infected with severe invasive group A *Streptococcus* isolates, but not with non-invasive group A *Streptococcus* isolates, exhibit high concentrations of plasma interferon- $\gamma$  during the early stage of infection. Interferon- $\gamma$  is necessary to protect mice, and is produced by a novel population of granulocyte-macrophage colony-stimulating factor-dependent immature myeloid cells with ring-shaped nuclei. These interferon- $\gamma$ -producing immature myeloid cells express monocyte and granulocyte markers, and also produce nitric oxide. The adoptive transfer of interferon- $\gamma$ -producing immature myeloid cells have a protective role during the early stage of severe invasive group A *Streptococcus* infections.

Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Department of Bacteriology I, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Correspondence and requests for materials should be addressed to M.A. (email: ato@nih.go.jp).

treptococcus pyogenes (group A Streptococcus; GAS) is one of the most common human pathogens. It causes a wide variety of infections, ranging from uncomplicated pharyngitis and skin infections to severe and even life-threatening manifestations such as streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis. The mortality rates for STSS and necrotizing fasciitis are high (30–70%), even following prompt antibiotic therapy and debridement<sup>1–4</sup>.

It is widely believed that myeloid cells including polymorphonuclear leukocytes (PMNs) have a central role in survival from GAS infections, and interferon (IFN)- $\gamma$  is essential to full activation and proper function of PMNs. Notably, IFN- $\gamma$  at the infection site is thought to be critical for protection; however, its increased systemic levels seem to be detrimental to survival after GAS infections<sup>5</sup>. Therefore, the appropriate regulation of cytokine-producing cells may be critical for survival and host defense against severe invasive GAS infections.


Myeloid cells with ring-shaped nuclei (ring cells) are present in the peripheral blood of patients with myeloproliferative diseases, but only rarely in healthy control subjects<sup>6,7</sup>. Ring cells are usually referred to as PMNs. However, not only Gr-1high PMN-like ring cells, but also Gr-1low mononuclear cell-like ring cells are present in the bone marrow, peripheral blood, and inflammatory infiltrates of mice<sup>8</sup>. Morphologically, a part of myeloid-derived suppressor cells (MDSCs) has ring-shaped nuclei<sup>9,10</sup>. MDSCs are potent suppressors of T-cell immunity, and their presence is associated with a poor clinical outcome in cancer. They are divided into 2 subtypes according to morphology and surface markers: Ly-6G<sup>-</sup> Ly-6C<sup>high</sup> monocytic MDSCs and Ly-6G+ Ly-6Clow granulocytic MDSCs11,12. Recent studies have demonstrated the considerable suppressive potential of MDSCs on T-cell immunity in autoimmune diseases, and also in chronic infections with intracellular pathogens, such as Salmonella typhimurium, Candida albicans, Trypanosoma cruzi, and Toxoplasma gondii<sup>13</sup>. However, the biological functions of ring cells in infectious diseases, and also the relationship between ring cells and MDSCs, remain largely unknown.

In the present study, IFN- $\gamma$ -producing immature myeloid cells with ring-shaped nuclei ( $\gamma$ IMCs), which originated from bone marrow precursor-like cells (BMPCs), are shown to be functionally and phenotypically distinct from MDSCs. We demonstrate that  $\gamma$ IMCs have a protective role against severe invasive GAS infections, and possibly compensate for neutropenia.

#### Results

Role of IFN-y in severe invasive GAS infections. To clarify the types of cytokines involved in severe invasive GAS infections, we first investigated the dynamics of cytokines in severe invasive and non-invasive GAS infections. As a model of disseminated infection in normally sterile sites, we intraperitonially (i.p.) infected GASsusceptible C3H/HeN mice<sup>14–17</sup> with either severe invasive (emm3 genotype rgg gene-mutated STSS strain, NIH34) or non-invasive (emm3 genotype non-STSS (pharyngitis) strain, K33) GAS clinical isolates 18, and measured the levels of plasma cytokines. We detected no significant amount of plasma cytokines within 24h of infection. By contrast, in mice infected with severe invasive GAS isolates, but not with non-invasive GAS isolates, we detected high levels of plasma IFN-γ; moreover, the levels increased rapidly at 48 h post-infection (Fig. 1a). Other cytokines, such as IL-1α, IL-1β, IL-4, IL-5, IL-12 p70 and IL-17, were scarcely detected in the plasma of mice infected with either severe invasive or non-invasive isolates. By contrast, in mice infected with severe invasive GAS isolates, the levels of IL-2. IL-10, and TNF increased transiently at 36h post-infection.

Further, we evaluated whether IFN- $\gamma$  is the host factor contributing to protection against severe invasive GAS infections, or to deterioration of STSS through an augmented inflammatory process. We i.p. administered mice with an anti-mouse IFN- $\gamma$  neutralizing



**Figure 1 | IFN-**γ is a host defense factor in mice infected with severe invasive GAS isolates. (a) C3H/HeN mice were i.p. inoculated with *S. pyogenes (emm3* genotype) clinical isolates (non-STSS, K33; STSS, NIH34;  $3.0 \times 10^7$  CFU per mouse), and plasma cytokine levels were determined by FlowCytomix. Data are expressed as mean ±s.d. for at least 2 independent experiments, using a total of 6-10 mice for each group. The differences compared with K33-infected mice were statistically significant (\*P<0.05, \*\*P<0.01) as determined by Student's t-test. (b) C3H/HeN mice were i.p. inoculated with NIH34 (3.0×10<sup>7</sup> CFU per mouse) in the presence of an IFN-γ neutralizing mAb (clone R4-6A2) (1mg per mouse) or control rat IgG (1mg per mouse). Survival was observed for 4 days post-infection. Mortality differences compared with infected mice in the presence of control IgG were statistically significant (\*P<0.05), as determined by a log-rank test. Survival curves were generated from two independent experiments, using a total of eight mice for each group.

mAb (clone R4-6A2), on the day of infection with severe invasive GAS isolates. At 72h post-infection, all of the mice administered with the IFN- $\gamma$  neutralizing mAb died. By contrast, 50% of the mice treated with rat IgG as a control survived (Fig. 1b). These results are consistent with those of a previous study<sup>5</sup>, in which mice treated with a different IFN- $\gamma$  neutralizing mAb (clone XMG1.2) and IFN- $\gamma$  knockout (Ifng<sup>-/-</sup>) mice were more susceptible to lethal skin infection with the M-nontypeable GAS strain 64/14 than were control IgG-administered mice and wild-type mice, respectively. Thus, IFN- $\gamma$  may act as a host defense factor against severe invasive GAS infections.

A source of IFN-y in severe invasive GAS infections. It is widely believed that T cells are a main source of IFN- $\gamma$  in severe invasive GAS infections  $^{19-21}$ . To identify the IFN- $\gamma$ -producing cell types in mice infected with severe invasive GAS isolates, we used an *in vivo* intracellular cytokine synthesis (ICS) assay  $^{22,23}$  to assess splenic IFN- $\gamma$  production at 48 h post-infection. Unexpectedly, we revealed that Gr-1+ CD11b+ cells (but not TCR- $\beta$ + TCR- $\gamma/\delta$ +, CD4+, or CD8+ T cells, DX5+ NK/NKT cells, or CD11c+ MHC-II+ dendritic cells) were a source of splenic IFN- $\gamma$  in superantigen-insensitive C57BL/6 mice  $^{24,25}$ , and also in C3H/HeN mice (Fig. 2a and b). These Gr-1+ cells appeared in the spleen on day 1 post-infection, subsequently increased in number, and were the major source of IFN- $\gamma$ 




Figure 2 | CD11b  $^+$  Gr-1  $^+$  cells are the source of IFN- $\gamma$  in severe invasive GAS infections. (a,b) C3H/HeN mice (a), C57BL per six mice (WT) (b), and  $Rag1^{-/-}$  mice (b) with or without i.p. infection of NIH34 (3.0×10<sup>7</sup> CFU per mouse) for 42 h were i.v. injected with monensin. Six hours later, the mice were sacrificed and their splenocytes were immediately stained for the indicated markers, and analysed by ICS assay. (a) The numbers (%) in the plots represent the proportion of IFN- $\gamma^+$  subsets to total splenocytes. (b) Lower panels show the cells gated on the IFN- $\gamma^+$  population. Data are representative of three independent experiments. (c,d) WT and  $Rag1^{-/-}$  mice were i.p. inoculated with NIH34 (3.0×10<sup>7</sup> CFU per mouse) in the absence (c) or presence (d) of an IFN- $\gamma$  neutralizing mAb (clone R4-6A2) or control rat IgG (1mg per mouse) as in Fig. 1b. Survival (in days) was observed as indicated. Survival curves were generated from 2 independent experiments, using a total of 12 mice for each group. (d) Mortality differences compared with infected mice in the presence of control IgG were statistically significant (\*P<0.05) as determined by a log-rank test.

throughout infection (Supplementary Fig. S1). By contrast,  $TCR-\beta^+$  T cells and DX5+ or NK1.1+ NK cells, which are regarded as the sources of IFN- $\gamma$  in GAS infections<sup>15–17</sup>, produced small amounts of IFN- $\gamma$  during the late stage (days 3–5 post-infection) of severe invasive GAS infections in C3H/HeN mice, but not in C57BL/6 mice. Notably, the accumulation of Gr-1+ cells led to the clearance of infection from the spleen. Additionally, the administration of monensin, which blocks intracellular cytokine transport, did not induce spontaneous splenic production of IFN- $\gamma$  (Fig. 2a and b; Supplementary Fig. S1).

To exclude the involvement of T cells in protection against severe invasive GAS infections, we investigated IFN- $\gamma$  production in C57BL/6.RAG1 knockout ( $Rag1^{-/-}$ ) mice, which have no mature B and T cells<sup>26</sup>. The ICS assay revealed that the cellular source of IFN- $\gamma$  during severe invasive GAS infections was Gr-1<sup>+</sup> CD11b<sup>+</sup> cells in  $Rag1^{-/-}$  mice, and also in C57BL/6 wild-type (WT) mice (Fig. 2b). We further examined the mortality of  $Rag1^{-/-}$  mice during severe invasive GAS infections. We observed no significant difference in mortality between  $Rag1^{-/-}$  and WT mice infected with severe invasive GAS isolates (Fig. 2c). Furthermore, similar to C3H/HeN mice (Fig. 1b), IFN- $\gamma$  neutralizing mAb (clone R4-6A2)-

treated  $Rag1^{-/-}$  mice were more susceptible to severe invasive GAS infections than were control IgG-administered  $Rag1^{-/-}$  mice (Fig. 2d). Our results indicate that mature B and T cells do not affect the mortality of infected mice, and that T cells have no protective effect during the early stage of severe invasive GAS infections.

Characterization of the early source of IFN- $\gamma$ . Anti-Gr-1 mAb detects Ly-6C+ monocytes and Ly-6G+ PMNs. Therefore, to determine which subset of Gr-1+ CD11b+ cells is responsible for IFN- $\gamma$  production during severe invasive GAS infections, we investigated the surface phenotype of IFN- $\gamma$ -producing cells isolated from the spleens of mice at 48 h post-infection. The ICS assay revealed that IFN- $\gamma$ -producing cells had the phenotype of monocytes (F4/80low CX3CR1+) and PMNs (Ly-6G+ Ly-6Clow) (Fig. 3). Additionally, they expressed no lymphoid (CD27, IL-7R $\alpha$ ) or granulocyte-lineage (CCR3, Siglec-F, c-Kit, IL-5R $\alpha$  (H7)) markers, but exhibited particular profiles of CCR2- CD31+ CD34- CD38+ CD44high CD49d+ CD62L+ CD69+ IL-5R $\alpha$  (T21)high Siglec-H- (Fig. 3; Supplementary Table S1). In this model, the most prominent GAS infection was present in the kidney 18,27. In accordance with the bacterial burden in the peritoneal cavity, spleen and kidney, a higher proportion




Figure 3 | IFN- $\gamma$ -producing cells exhibit monocyte and PMN phenotypes in severe invasive GAS infections. C3H/HeN mice with or without i.p. infection of NIH34 (3.0×10<sup>7</sup> CFU per mouse) for 42 h were i.v. injected with monensin. Six hours later, the mice were killed and their splenocytes were immediately stained for the indicated markers, and analysed by the ICS assay. The numbers (%) in the plots represent the proportion of IFN- $\gamma$ <sup>+</sup> subsets to total splenocytes. These data are representative of three independent experiments.

of IFN-γ-producing cells accumulated in the kidney of C3H/HeN mice, and also C57BL/6 mice i.p. infected with NIH34 (Supplementary Fig. S2). By contrast, lower proportion of IFN-γ-producing cells existed at the sites of infection. A skin-infection model yielded similar results (Supplementary Fig. S2). Furthermore, IFN-γ-producing cells were detected in the spleens from mice infected with various STSS strains<sup>18,27</sup> (Supplementary Fig. S3). These cells were also detected in the peripheral blood and (in particularly high frequency) the bone marrow from NIH34-infected mice (Fig. 4a-d; Supplementary Fig. S4). Interestingly, Siglec-F+ eosinophils (Eos) stained with IL-5Rα (H7) and IL-5Rα (T21), whereas IFN-γ-producing cells stained well with T21, but not with H7 (Fig. 4e), suggesting that IFN-γ-producing cells were phenotypically distinct from Eos. IFN-γ-producing cells were also phenotypically distinct from Ly-6Clow CD31 - PMNs (Fig. 4d). Moreover, the number and proportion of PMNs were markedly reduced in the spleen, peripheral blood, and bone marrow at 48h post-infection (Fig. 4d and f), as reported in human STSS cases<sup>28</sup>.

Immature myeloid cells as an early source of IFN-γ. The IFN-γ-producing cells expressed the phenotypic markers of monocytes/macrophages (F4/80 and CX3CR1) and PMNs (Ly-6G). Therefore,

we sorted CD11b+ CD11c- F4/80low Ly-6G+ cells from the spleens of infected mice and morphologically analysed them with May-Grünwald-Giemsa staining. The IFN-γ-producing CD11b+ CD11c F4/80<sup>low</sup> Ly-6G<sup>+</sup> splenocytes were IMCs, but not monocytes/ macrophages or PMNs. These IFN-γ-producing IMCs were large cells containing ring-shaped, non-segmented nuclei, with a coarse chromatin pattern<sup>6-8</sup> (Fig. 5a and b). The sorted cells were contaminated with a small number of PMNs; however, immunohistochemical analyses showed that IMCs, but not PMNs, were the source of IFN-7 (Fig. 5c). The cells with ring-shaped nuclei were also observed in the peritoneum, kidney, and spleen from i.p. infection model, and in the skin from subcutaneous (s.c.) infection model, whereas such cells were not observed in the spleen and kidney from non-infected or non-invasive K33 strain-infected mice (Fig. 5d and e). To determine whether IFN-γ-producing IMCs (γIMCs) are committed to the granulocyte or monocyte lineage, we cultured sorted CD11b+ CD11c-F4/80<sup>low</sup> Ly-6G<sup>+</sup> γIMCs in vitro, in the presence of G-CSF, M-CSF, GM-CSF or IL-5. We observed that G-CSF, M-CSF and IL-5 failed to promote differentiation and survival (Fig. 5f). By contrast, in the presence of GM-CSF, differentiated yIMCs increased their expression of CD11c, F4/80, DX5 and Siglec-F (Fig. 5g) with the polymorphonuclear phenotype (Fig. 5h). Such granulocyte-like cells showed




Figure 4 | IFN- $\gamma$ -producing cells are detected in the peripheral blood and the bone marrow of GAS-infected mice. (a-d) Non-infected C3H/HeN mice or (a-e) mice i.p. infected with NIH34 (3.0×10<sup>7</sup> CFU per mouse) for 42 h were i.v. injected with monensin. Six hours later, the mice were killed and their splenocytes (a-e), peripheral blood cells (a,b), and bone marrow cells (c,d) were immediately stained for the indicated markers, and analysed by ICS assay. (a,c) The numbers (%) in the plots represent the proportion of IFN- $\gamma$ <sup>+</sup> subsets to total cells. (b,d,e) Lower panels show the cells gated on the IFN- $\gamma$ <sup>+</sup> population. (d,e) Rectangle gates in the plot represent mature granulocytes (d) and Eos (e). The numbers (%) in the plots represent the proportion of mature granulocytes (d) or IFN- $\gamma$ <sup>+</sup> Eos (e) to total cells. Data are representative of three independent experiments. (f) The numbers of PMNs in the bone marrow, peripheral blood, and spleen from non-infected or NIH34-infected mice at 48 h. Data are expressed as mean ±s.d. (n = 3). The differences compared with non-infected mice were statistically significant (\*P<0.05, \*\*P<0.01) as determined by Student's t-test.

reduced ability to produce IFN- $\gamma$  (Fig. 5i), and were phenotypically different from c-Kit<sup>low</sup> H7<sup>+</sup> Siglec-F<sup>+</sup> bone marrow-derived Eos and CCR3<sup>+</sup> H7<sup>+</sup> Siglec-F<sup>+</sup> splenic Eos<sup>29</sup>; (Supplementary Fig. S5). These results suggest that  $\gamma$ IMCs are committed to the granulocyte lineage, but do not exist in the steady state, and produce IFN- $\gamma$  during a specific stage of differentiation.

Nitric oxide (NO) is considered to be a main mechanism for controlling some infective agents. Myeloid cells are able to release NO in response to IFN- $\gamma^{30-33}$ ; moreover, IFN- $\gamma$  and NO-producing myeloid cells have been described in cancer<sup>34</sup>. Therefore, we investigated the ability of  $\gamma$ IMCs to produce NO in response to GAS. When stimulated by autocrine and/or paracrine IFN- $\gamma$ ,  $\gamma$ IMCs (but not than PMNs and granulocyte-like cells differentiated from  $\gamma$ IMCs using GM-CSF) were able to produce NO, because their NO production was significantly blocked in the presence of IFN- $\gamma$  neutralizing mAb (Fig. 5j).

Differentiation of precursor-like cells into γIMCs. Bone marrow contains the highest proportion of γIMCs (Fig. 4c and d). Therefore, we attempted to identify the precursors of γIMCs in the bone marrow of mice infected with severe invasive GAS isolates. Interestingly, analysis of the surface molecules revealed 2 distinct subsets of IFN-γ-producing cells (Fig. 6a): a minor and a major subset. The minor subset constituted 6.9±3.2% of IFN-γ-producing bone marrow cells (Fig. 6b), and comprised CD11b+ CD11c- F4/80low Ly-6G+ large cells (Supplementary Fig. S6), containing ring-shaped nuclei (BM-γIMCs) (Fig. 6c). On the basis of morphology and surface phenotype, these cells corresponded to splenic γIMCs (Sp-γIMCs) (Fig. 5a and b). Neither isolated BM-γIMCs nor Sp-γIMCs proliferated in the presence of GM-CSF (Figs 5f and 6d). These cells differed from metamyelocytes and immature neutrophils in non-infected bone

marrow (Fig. 6c). The major subset of IFN- $\gamma$ -producing cells comprised CD11b+ CD11clow F4/80+ Ly-6Glow precursor-like cells (BMPCs) (Fig. 6b; Supplementary Fig. S6), which constituted  $74.8\pm13.7\%$  of IFN- $\gamma$ -producing cells (Fig. 6b). This subset consisted of ~10% monocyte-like ring cells and immature myeloid cells (Fig. 6c), which are phenotypically different from CD11b - Ly-6Gcells such as granulocyte-monocyte progenitors, common myeloid progenitors, and myelolymphoid progenitors<sup>35</sup>. In the presence of GM-CSF, isolated BMPCs proliferated (Fig. 6d) and differentiated into BM-yIMCs (Fig. 6c and e). Moreover, after 2 extra days of incubation with GM-CSF, differentiated BM-yIMCs increased their expression of CD11c, F4/80, DX5 and Siglec-F (Fig. 6f). The polymorphonuclear and cell surface phenotype (Supplementary Fig. S6) was similar to that of Sp-γIMCs cultured with GM-CSF (Fig. 5g and h). The differentiation of BMPCs into BM-yIMCs was totally blocked in the presence of IFN-y neutralizing mAb; by contrast, this cytokine was dispensable for differentiation into granulocyte-like cells (Supplementary Fig. S6). These results are in accordance with the absence of Ly-6G<sup>+</sup>  $\gamma$ IMCs in the spleen of GAS-infected C57BL6.Ifng<sup>-/-</sup> mice (Supplementary Fig. S7). The expression level of Ly-6G in PMNs was similar for WT and Ifng<sup>-/-</sup> mice (Supplementary Fig. S7). As with YIMCs and YIMC-differentiated granulocyte-like cells (Fig. 5i), the cells differentiated from BMPCs, after 2 extra days of incubation with GM-CSF, retained the ability to release IFN-γ in response to GAS; however, subsequent differentiation by GM-CSF reduced the ability to produce IFN-7 (Fig. 6g). A few IFN-7-producing cells in non-infected mice were recognized in the same fraction as the BMPCs (Fig. 6a), and, therefore, it is possible that BMPCs exist in the naïve bone marrow. Our results suggest that IFN-7-producing BMPCs are the precursors of yIMCs, and that their differentiation is dependent on autocrine and/or paracrine pathways involving




Figure 5 |  $\gamma$ IMCs are the source of IFN- $\gamma$  in severe invasive GAS infections. (a) CD11b<sup>+</sup> CD11c<sup>-</sup> F4/80<sup>-</sup> Ly-6G<sup>high</sup> PMNs in splenocytes from non-infected C3H/HeN mice, or CD11b<sup>+</sup> CD11c<sup>-</sup> F4/80<sup>low</sup> Ly-6G<sup>+</sup>  $\gamma$ IMCs in splenocytes from mice infected with NIH34, were isolated by FACS. (b,c) Cytospin preparations of each sorted cell type were visualized with May-Grünwald-Giemsa staining (b), whereas intracellular IFN- $\gamma$  (green, IFN- $\gamma$ ; red, nuclei) was visualized with a confocal laser microscopy (c). Scale bars, 20  $\mu$ m. (d,e) Paraffin-embedded sections of peritoneum, from mice i.p. infected with NIH34 and skin from mice subcutaneously (s.c.) infected with NIH34 for 48 h (d), and of spleen and kidney from mice i.p. infected with or without K33 or NIH34 for 48 h, (e) were visualized with hematoxylin and eosin staining. The yellow arrows indicate the cells with ring-shaped nuclei. Scale bars, 100  $\mu$ m. (f) Sorted IMCs were cultured with control medium (Med), G-CSF (50 ng ml<sup>-1</sup>), M-CSF (10 ng ml<sup>-1</sup>), or IL-5 (10 ng ml<sup>-1</sup>) for 2-4 days, and their absolute numbers were counted on the indicated days. Data are expressed as the average (mean±s.d.) of triplicate wells (n=3). The differences compared with Med were statistically significant (\*\*P<0.01) as determined by Student's t-test. (g)  $\gamma$ IMCs (blue line) and GM-CSF (2 days)-cultured  $\gamma$ IMCs (GM2- $\gamma$ IMCs were visualized with May-Grünwald-Giemsa staining. Scale bars, 20  $\mu$ m. (i,j)  $\gamma$ IMCs and GM2- $\gamma$ IMCs were cultured with erythromycin-treated NIH34 (MOI 100) in the presence of control rat IgG or an IFN- $\gamma$  neutralizing mAb (clone R4-6A2) for 24 h. The levels of IFN- $\gamma$  (i) and NO<sub>2</sub><sup>-</sup> (j) in the culture supernatants were measured by ELISA and Griess reagent system, respectively. The average (mean±s.d.) of triplicate wells is shown. Statistical significance (\*\*P<0.01) was determined by ANOVA.

IFN-γ. Notably, the BMPC-derived unclassified granulocyte-lineage, such as γIMCs (but not immature PMNs), seems to appear during severe invasive GAS infections.

Distinction between  $\gamma$ IMCs and MDSCs. MDSCs are composed of F4/80 $^-$  or F4/80<sup>low</sup> granulocytic MDSCs with ring-shaped nuclei, and F4/80 $^+$  monocytic MDSCs<sup>10,11</sup>. They can produce IFN- $\gamma$ <sup>13</sup>. Furthermore, granulocytic/monocytic MDSCs differentiate into CD11c $^+$  F4/80 $^+$  Gr-1 $^+$  cells<sup>12</sup>, as do  $\gamma$ IMCs (Fig. 5g). To identify the relationship between the types of  $\gamma$ IMCs observed during severe invasive GAS infections and MDSCs, we investigated the ability of

γIMCs to suppress T-cell responses. As reported previously, *in vitro* differentiated Ly-6C+ Ly-6Glow F4/80+ MDSCs<sup>9</sup> spontaneously produced IFN-γ (Fig. 7a), and inhibited Ag-specific T-cell proliferation and IFN-γ production from T cells (Fig. 7b). Conversely, purified γIMCs failed to inhibit T-cell responses (Fig. 7c), suggesting that γIMCs are functionally distinct from MDSCs. Additionally, MDSCs markedly decreased in number and lost the ability to produce IFN-γ when cultured *in vitro* with severe invasive GAS isolates (Fig. 7a). Furthermore, CCR2 $^-$  CX3CR1 $^+$  CD31 $^+$  γIMCs are phenotypically different from CCR2 $^+$  CX3CR1 $^-$  CD31 $^-$  granulocytic MDSCs and CCR2high CX3CR1 $^-$  CD31 $^+$  monocytic MDSCs (Supplementary




Figure 6 | BMPCs differentiate into yIMCs in the presence of GM-CSF. (a) C3H/HeN mice non-infected or i.p. infected with NIH34 (3.0×10<sup>7</sup> CFU per mouse) for 42 h were i.v. injected with monensin. Six hours later, the mice were killed and their bone marrow cells were immediately stained for the indicated markers, and analysed by ICS assay. Lower panels show the cells gated on the IFN- $\gamma^+$  population. The numbers (%) in the plots represent the proportion of PMNs, BM- $\gamma$ IMCs, and BMPCs to total (upper panels) and IFN- $\gamma$ <sup>+</sup> (lower panels) bone marrow cells. (b) Proportion (%) of BM- $\gamma$ IMCs, and BMPCs to total (upper panels) and IFN- $\gamma$ <sup>+</sup> (lower panels) bone marrow cells.  $\gamma$ IMCs and BMPCs to bone marrow cells (upper panel) or IFN- $\gamma$ -producing bone marrow cells (lower panel). Data are expressed as mean  $\pm$  s.d. (n = 3). The differences compared with the proportion of BM- $\gamma$ IMCs were statistically significant (\*\*P<0.01) as determined by Student's t-test. (c) Cytospin preparations of sorted PMNs, BM-yIMCs, BMPCs, and GM-CSF (2 days)-cultured BMPCs (GM2-BMPCs) were visualized with May-Grünwald-Giemsa staining. Arrowheads indicate stab neutrophils or metamyelocytes. Scale bars, 20 µm. (d) Sorted BMPCs and BM-γIMCs were cultured with GM-CSF  $(10 \text{ ng ml}^{-1})$  for 2-6 days, and their absolute numbers were counted on the indicated days. Data are expressed as mean  $\pm$  s.d. (n=3). The differences in proliferation increase were statistically significant (\*P<0.05, \*\*P<0.01) as determined by Student's t-test. (e) Flow cytometry profile of infected bone marrow cells (left), sorted BMPCs (middle), and GM2-BMPCs (right). Rectangles show a sorting gate of BMPCs. (f) GM-CSF-cultured BMPCs (2 days or 4 days; GM2-BMPCs, blue line; GM4-BMPCs, red line) and BM-γIMCs (2 days; GM2-BM-γIMCs, green line) were stained for the indicated markers. Data are representative of 3 independent experiments. (g) IFN-γ production from BMPCs. GM2-BMPCs or GM4-BMPCs were cultured with erythromycin-treated NIH34 (MOI 100) in the presence of control rat IgG or an IFN-γ neutralizing mAb (clone R4-6A2) for 24 h. The level of IFN-γ in the culture supernatants was measured by ELISA. The average (mean  $\pm$  s.d.) of triplicate wells is shown. Statistical significance (\*P<0.05) was determined by Student's t-test.

Table S1). Taken together, our results indicate that  $\gamma$ IMCs, which appear in association with severe invasive GAS infections, comprise a novel subset of IFN- $\gamma$ -producing cells, but not MDSCs.

Role of yIMCs in severe invasive GAS infections. To elucidate the protective role of YIMCs, we employed an adoptive transfer system using WT or Ifng<sup>-/-</sup> mice. CD11b<sup>+</sup> CD11c<sup>-</sup> F4/80<sup>low</sup> Ly-6G+ YIMCs were purified from the spleens of WT mice infected with severe invasive GAS at day 2, and transferred into recipient mice. These mice were infected with a lethal dose of severe invasive GAS isolates ( $5 \times 10^7$  CFU (high dose)/WT mouse,  $1 \times 10^7$  CFU (low dose)/Ifng-/- mouse), and the bacterial loads (CFUs) in the blood were quantified. At 24 h post-infection, yIMC-recipients and IFNy-treated mice had significantly lower bacterial loads in the blood than did control mice (Fig. 8a-c). Additionally, all control mice and all IFN-γ-treated mice died. By contrast, 100% of high dose-infected WT recipients and low dose-infected Ifng<sup>-/-</sup> recipients of  $\gamma$ IMCs, and also low dose-infected WT mice, survived until 60h postinfection (Fig. 8d-f). Our results indicate that IFN-y successfully improved the bacterial clearance, but that systemic IFN-y treatment was detrimental to survival following GAS infections (Fig. 8a,c,d

and f). Thus, it appears that  $\gamma IMCs$  have a protective role in severe invasive GAS infections.

#### Discussion

Previous studies have indicated that T cells and NK cells may have a role in the production of IFN- $\gamma$  during GAS infections<sup>5,15-17,19-21</sup>. In the present study, we have demonstrated for the first time that  $\gamma$ IMCs in the peritoneal cavity, skin, spleen, kidney, peripheral blood and bone marrow (but not T cells or NK cells) produce IFN- $\gamma$  in vivo during the early stage of severe invasive GAS infections. The intensity of IFN- $\gamma$  production is comparable among  $\gamma$ IMCs, T cells, and NK cells, but production by  $\gamma$ IMCs takes place sooner than that by T cells and NK cells. Moreover, throughout the course of GAS infection,  $\gamma$ IMCs are the main IFN- $\gamma$ -producing cells in the spleen. We further observed that IFN- $\gamma$  neutralized  $Rag^{-/-}$  mice succumbed to severe GAS infection at a similar rate to WT mice. Taken together, our results indicate that  $\gamma$ IMCs comprise the major source of IFN- $\gamma$  during the early stage of severe invasive GAS infections, and that they have an important protective role.

Notably, IFN- $\gamma$  administration reduced the number of bacteria in the blood, whereas the transfer of  $\gamma$ IMCs, but not of IFN- $\gamma$ ,




Figure 7 |  $\gamma$ IMCs are functionally different from MDSCs. (a) C57BL/6 mouse bone marrow-derived MDSCs were differentiated *in vitro* with 40 ng ml<sup>-1</sup> GM-CSF for 4 days. MDSCs were then incubated with or without severe invasive GAS isolates (NIH34; MOI 1) in the presence of brefeldin A (10  $\mu$ g ml<sup>-1</sup>). Three hours later, the cells were immediately stained for F4/80, Ly-6G, and IFN- $\gamma$ , and analysed by ICS assay. Lower panels show the cells gated on the IFN- $\gamma$ <sup>+</sup> population. (b,c) CD11b<sup>+</sup> CD11c<sup>-</sup> Ly-6C<sup>+</sup> Ly-6G<sup>low</sup> *in vitro*-differentiated MDSCs, and CD11b<sup>+</sup> CD11c<sup>-</sup> F4/80<sup>low</sup> Ly-6G<sup>+</sup>  $\gamma$ IMCs, in the spleen from C57BL per six mice infected with NIH34 (3.0×10<sup>7</sup> CFU per mouse) for 48 h were isolated by FACS. Purified MDSCs (b) or purified  $\gamma$ IMCs (c) were cultured at the indicated ratio with 2.0×10<sup>5</sup> splenocytes from C57BL/6.OT-I mice in the presence of antigenic OVA<sub>357-364</sub> peptides. Cell proliferation was measured using [ $^3$ H] thymidine uptake, and the level of IFN- $\gamma$  in the culture supernatants was measured by ELISA. Each experiment was performed in triplicate. Mean±s.d. is shown. The differences compared with OT-I splenocytes alone were statistically significant ( $^4$ P<0.05,  $^{**}$ P<0.01) as determined by ANOVA. Data are representative of three independent experiments.

improved the survival rate of mice following GAS infection. Therefore, IFN-γ was necessary, but not sufficient, to protect mice from severe invasive GAS infections. We propose that NO production from γIMCs (which is restrictively controlled by IFN-γ), perhaps combined with that from other myeloid cells, may have a critical defensive role during the early stage of infection. In systemic GAS infection, γIMCs are deployed in various infected tissues; thus, the derived IFN-γ, NO, and/or as yet unidentified protective factors may promote the development of innate immune responses for the activation of phagocytes. However, we were unable to exclude the possibility that excessive quantities of IFN-γ secreted by T cells following superantigens stimulation, by NK cells, and even by γIMCs at the late stage of infection, are detrimental to survival following GAS infections, by exacerbating inflammatory responses and organ injury.

 $\gamma$ IMCs express phenotypic markers of the monocyte/macrophage and granulocyte lineages, and are phenotypically different from other Ly-6C+ cells, such as inflammatory and resident monocytes 11,36. Mature PMNs, immature PMNs, and their progenitors proliferate or maintain their survival in the presence of G-CSF<sup>37</sup>. By contrast, in the present study, γIMCs did not survive in the presence of G-CSF. However, in the presence of GM-CSF, they differentiated into a PMN-like phenotype. Thus, yIMCs are distinct from the PMN lineage that develops during steady-state haematopoiesis. In the presence of GM-CSF,  $\gamma$ IMCs possessed the ability to express a specific marker for Eos, Siglec-F. Nevertheless, based on staining with H7 and T21, they were distinct from Siglec-F+ splenic Eos. Our observation that γIMCs failed to proliferate in response to IL-5 are consistent with the previous finding that T21 mAb may recognize IL-5Rα and other myeloid cell surface protein(s)<sup>38</sup>. Thus, γIMCs are unlikely to be committed to an Eos lineage; similarly, they are phenotypically different from DX5+ basophils and basophil lineage-committed progenitors<sup>39</sup>.

Granulocytic MDSCs are very similar to  $\gamma$ IMCs in terms of surface markers (CD11b, F4/80, Ly-6C, Ly-6G, CD44, CD49d, and CD62L)<sup>10,11</sup>, dependency on a growth factor (GM-CSF)<sup>12</sup>, and cytokine production profile (IFN- $\gamma$ )<sup>13</sup>. However, in the present

study, we reveal that MDSCs did not produce IFN- $\gamma$  in response to *in vitro* GAS infections. This is consistent with the previous finding that MDSCs from septic mice did not produce IFN- $\gamma^{40}$ . MDSCs are believed to originate from, or be accelerated by, the blockade of normal haematopoiesis during chronic inflammation or in a tumourbearing state.  $\gamma$ IMCs and MDSCs may therefore be closely related cell populations, and their differentiation and function may be regulated by the host circumstances.

On the basis of our present findings, we conclude that  $\gamma IMCs$  are committed to an unclassified granulocyte lineage with an immature phenotype, and that such cells have the potential to replenish granulocyte populations. Moreover, GM-CSF is essential for the extraordinary state, such as severe systemic infection, but not for normal haematopoiesis<sup>41</sup>. The replacement of GM-CSF-dependent  $\gamma IMCs$  may be regarded as a marked shift to the left of the leukocyte differential, with many immature granulocytes in automated cell counting. This is a characteristic of severe invasive GAS infections in our mouse model and also in human diseases<sup>4,28</sup>. The role of  $\gamma IMCs$  in other infections and inflammatory diseases remains to be elucidated.

In the present study, we reveal that γIMCs differentiate from a subpopulation of CD11b+ CD11clow F4/80+ Ly-6Glow cells in the bone marrow; this is known as a monocyte lineage. No YIMCs were detected in Ifng<sup>-/-</sup> mice infected with GAS, and IFN-γ-producing BMPCs (but not \gamma IMCs) failed to differentiate into granulocyte-like cells in the presence of an IFN-y neutralizing mAb. These observations suggest that the generation of YIMCs depends on the production of IFN-γ by BMPCs themselves. IFN-γ derived from BMPCs and MMCs may be a key component of haematopoiesis during innate and adaptive immune responses, as shown in cases of malaria and Mycobacterium avium infection 35,42. In the steady state, a few IFN-γ-producing cells existed in the Ly-6Clow CD31+ fraction, including mixed progenitors of bone marrow<sup>43</sup>. Thus, we cannot exclude the possibility that BMPCs exist in non-infected bone marrow and have potential to produce IFN-y, and that a subset of bone marrow cells can produce IFN-γ for the reproduction of haematopoietic stem cells<sup>42</sup>.




Figure 8 |  $\gamma$ IMCs participate in protection against severe invasive GAS infections. (a-f) CD11b + CD11c - F4/80 low Ly-6G +  $\gamma$ IMCs in the spleen from C57BL/6 WT mice infected with NIH34 (3.0×10<sup>7</sup> CFU per mouse) for 48 h were isolated by FACS. WT or  $Ifng^{-/-}$  mice i.v. received 3.0×10<sup>6</sup>  $\gamma$ IMCs, or were i.p. treated with IFN- $\gamma$  (10 ng per mouse). (a,d) WT mice (n=5), WT recipients of  $\gamma$ IMCs (n=5), and mice i.p. treated with IFN- $\gamma$  (n=6) were i.p. inoculated with NIH34 (5.0×10<sup>7</sup> CFU per mouse). (b,e) WT mice (n=5),  $Ifng^{-/-}$  mice (n=5), and  $Ifng^{-/-}$  recipients of  $\gamma$ IMCs (n=5) were i.p. inoculated with NIH34 (1.0×10<sup>7</sup> CFU per mouse). (c,f)  $Ifng^{-/-}$  mice (n=5) and  $Ifng^{-/-}$  mice i.p. treated with IFN- $\gamma$  (n=5) were i.p. inoculated with NIH34 (1.0×10<sup>7</sup> CFU per mouse). (a,b,c) The CFU of NIH34 in the peripheral blood was determined at 24 h post-infection. The differences compared with NIH34-infected WT mice (a) or NIH34-infected  $Ifng^{-/-}$  mice (b,c) were statistically significant (\*P<0.05) as determined by the Mann-Whitney *U*-test. (d,e,f) Survival was observed for 60 h post-infection. Data are representative of two independent experiments.

Ring cells are present in the blood and bone marrow of humans, especially patients with chronic myeloproliferative diseases<sup>6–8</sup> but only rarely in healthy control subjects<sup>7</sup>. Further investigations of peripheral blood leukocytes or bone marrow cells from severe invasive GAS patients are required, to clarify whether the human counterpart of  $\gamma$ IMCs is a major source of IFN- $\gamma$  in STSS patients.

PMNs are known to be essential for protection against non-invasive streptococcal infections. Following infection with severe invasive strains, PMNs are impaired by enhanced virulence factors (for example, streptolysin O)^{18,27}, and therefore other protective mechanisms are required for the recovery. The results of our present study indicate that  $\gamma IMCs$ , a novel class of differentiated granulocytic ring cells, which comprise the major source of IFN- $\gamma$  during the early phase of severe invasive GAS infections, may have an important role. During the later stage of infection, IFN- $\gamma$  derived from T cells and NK cells may be detrimental to the host. Nevertheless, we believe that the orchestrated regulation of  $\gamma IMCs$  serves as a protective mechanism against severe invasive bacterial infections.

# Methods

**Bacterial strains**. The STSS criteria in this study are based on those proposed by the Working Group on Severe Streptococcal Infections<sup>44</sup>. The clinical isolates from STSS (NIH34 (*emm3* genotype), NIH230 (*emm49* genotype), NIH186 (*emm1* genotype), and NIH202-2 (*emm1* genotype)), and also from non-invasive infections (K33 (*emm3* genotype)), were collected by the Working Group for Beta-hemolytic Streptococci in Japan<sup>18,27</sup>.

**Mice**. All work performed using mice was carried out in accordance with the guidelines for animal care approved by National Institute of Infectious Diseases. C3H/HeN and C57BL/6 mice (male, 5–6-weeks-old) were purchased from SLC.

C57BL/6. $Rag1^{-/-}$  (ref. 26) and C57BL/6. $Ifng^{-/-}$  (ref. 45) mice were purchased from the Jackson Laboratory. All mice were maintained in a specific pathogen-free condition.

**GAS infections in a mouse model.** GAS were grown to late-log phase (OD<sub>600</sub> = 0.75–0.95). Then,  $1.0\times10^7$  CFU to  $5.0\times10^7$  CFU GAS, suspended in 0.5 ml PBS, were i.p. inoculated into 6–8-week-old male mice. In some experiments, mice were i.p. administered with 1 mg of an anti-mouse IFN-γ neutralizing mAb (clone R4-6A2) or control rat IgG, or 10 ng of recombinant mouse IFN-γ (Wako Pure Chemical Industries) at infection. Plasma production of CXCL10 (an IFN-γ-inducible protein) at 24h, after NIH34 infection, was used to assess the activity of inoculated IFN-γ (10 ng per mouse) in  $Ifng^{-I-}$  recipients  $Ifng^{-I-}$  mice, 230.1±58.2 pg ml<sup>-1</sup>; IFN-γ-treated  $Ifng^{-I-}$  mice, 468.2±147.2 pg ml<sup>-1\*</sup>; C57BL/6 mice as positive control, 460.6±126.9 pg ml<sup>-1\*</sup>). Data were expressed as mean±s.d. (n=5). The differences compared with  $Ifng^{-I-}$  mice were statistically significant (\*P<0.05) as determined by Student's t-test. Survival curves were compared using a log-rank test.

**Measurement of cytokines in plasma**. The plasma cytokine levels were determined by FlowCytomix (eBioscience) using a FACSCalibur flow cytometer (Becton, Dickinson and Company (BD)), according to the manufacturer's instructions.

Flow cytometry analysis. For the *in vivo* ICS assay<sup>22,23</sup>, at day 2 post-infection, mice were intravenously (i.v.) injected with 500 μl of a PBS solution containing 100 μg monensin (Sigma-Aldrich) at 6 h before collecting. Splenocytes, peripheral blood cells, bone marrow cells, and leukocytes in the peritoneal cavity, kidney, and skin were collected and rapidly processed on ice. Single-cell suspensions were prepared, and red blood cells were removed using an ammonium chloride lysis buffer. For the *in vitro* ICS assay, non-infected or infected cells were cultured with 10 μg ml<sup>-1</sup> brefeldin A (Sigma-Aldrich) for 3 h. One million cells were stained with Alexa Fluor 488-, FITC-, PE-, Alexa Fluor 647-, allophycocyanin (APC)-, or Pacific Blue-conjugated Abs (clones and suppliers, Supplementary Table S2) at 4 °C for 15 min. Nonspecific staining was blocked with an anti-mouse FcγR mAb (clone 2.4G2). Dead cells were excluded by 7-aminoactinomycin D (7-AAD; Sigma-Aldrich) staining. After washing, cells were fixed in 2% paraformaldehyde/PBS for 10 min and then permeabilized in 0.5% saponin/0.5% BSA/PBS (permeabilization